Ahead of closing $11.5B Acceleron buyout, Merck is on the hunt for more deals
Somewhere in Kenilworth, NJ, Merck’s CEO Robert Davis is doing the happy dance. If all goes according to plan, he’ll close out this year with the company’s $11.5 billion Acceleron buyout in the books, plus an expected $5 to $7 billion windfall from its antiviral Covid-19 pill. But why stop there?
On the pharma giant’s Q3 earnings call, the chief executive confirmed that more M&A deals — and big ones, at that — are coming.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 129,600+ biopharma pros reading Endpoints daily — and it's free.